Overall safety profile based on cabotegravir and rilpivirine SmPCs, frequently reported adverse events (AEs) include:[1–3]

Please see the SmPCs’ complete list of clinical considerations for prescribing VOCABRIA and REKAMBYS.

  • Rare and serious adverse events


    • One case of fatal pancreatitis with Grade 4 lipase and confounding factors (including history of pancreatitis) has been reported in ATLAS-2M, for which causality to the injection regimen could not be ruled out

    Cellulitis and abscess ISRs[1,2]

    • Cellulitis and abscesses were uncommon complications of intramuscular injection


    • Hepatotoxicity has been reported in a limited number of patients receiving VOCABRIA with or without known pre-existing hepatic disease
    • Monitoring of liver chemistries is recommended, and treatment with VOCABRIA + REKAMBYS should be discontinued if hepatotoxicity is suspected

AE=adverse event; SmPC=summary of product characteristics.


  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. REKAMBYS Summary of Product Characteristics. Janssen.
  3. EDURANT Summary of Product Characteristics. Janssen.

REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-230001 - August 2023

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.